Clinical trials: Covid19 Vaccine
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability…
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Trial name
- NCT04754594
- Testing
- BNT162b2
- Where
- 90 sites in United States, Brazil and 3 more
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Sars-CoV-2 Infection
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
The investigated product is a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Booster Vaccine candidate optimized for the Omicron/BA.2 variant.
- Trial name
- NCT05844202
- Testing
- Alveavax-v1.2, Janssen Ad26.COV2.S
- Where
- 8 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alvea Holdings, LLC
Multiple Sclerosis
Covid-19 Vaccine Immune Response in Multiple Sclerosis
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection.
- Trial name
- CoVaR-MS (NCT05269888)
- Testing
- Blood Test 1, Blood Test 2
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Vaccines, Adverse Effects, Injection Site Reaction
Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination
Pfizer - BioNTech (BNT162b2) COVID - 19 vaccine is the first vaccine to be approved for emergency use by FDA. The most commonly reported side effect of the BNT162b2 vaccination is mild-to-moderate pain at injection site, i.e.
- Trial name
- NCT05157230
- Testing
- exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
COVID-19 Respiratory Infection, SARS CoV 2 Infection
Pancoronavirus Vaccine Study in Healthy Adults
Coronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
- Conditions
- COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
- Trial name
- NCT06950177
- Testing
- CoV-RBD-scNP-001 and 3M-052-AF
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years…
- Trial name
- Covid-Peru (NCT04612972)
- Where
- Peru
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Universidad Peruana Cayetano Heredia
Covid19
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease.
- Trial name
- NCT04798001
- Testing
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
- Where
- 2 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Meissa Vaccines, Inc.
Covid19, Corona Virus Infection
Long-Term Experience and Health Effects of COVID-19
The purpose of this study is to gain on-going COVID-19 feedback/data to drive timely action locally and nationally in order to mitigate transmission.
- Conditions
- Covid19, Corona Virus Infection, Quality of Life, Risk Reduction
- Trial name
- NCT04477902
- Testing
- none - observational
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Altura
Vaccine Preventable Disease
Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations
A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants.
- Trial name
- CERC (NCT04765839)
- Testing
- Educational, culturally appropriate COVID-19 messages
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19 Virus Infection
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged…
- Trial name
- NCT04560881
- Testing
- Inactivated SARS-CoV-2 vaccine (Vero cell)
- Where
- 4 sites in Argentina
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Myocarditis
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.
- Trial name
- NCT06189053
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- ModernaTX, Inc.
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
Anaphylactic Reaction, Vaccine Reaction
Allergy and COVID-19 Vaccines
Prospective and retrospective multicenter study to estimate the proportion of patients who tolerated continuation of COVID-19 vaccination (absence of anaphylactic manifestations).
- Trial name
- COVALL (NCT05028257)
- Testing
- COVID-19 Vaccines
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19 Vaccination, Inflammation
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Analysis of humoral antibody and cytokine kinetics after vaccination with either BNT162b2 or ChAdOx1 nCoV-19 vaccine and factors influencing the vaccine immunogenicity
- Conditions
- COVID-19 Vaccination, Inflammation, Vaccine Immune Response, Vaccine Adverse Reaction
- Trial name
- NCT05315856
- Testing
- either BNT162b2 or ChAdOx1 vaccine
- Where
- 3 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Korea University Guro Hospital
Allogenic Hematopoietic Cell Transplant, CAR-T Therapy
COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to confirm the accepted hypothesis from the recommendations of The European Society for Blood and Marrow…
- Conditions
- Allogenic Hematopoietic Cell Transplant, CAR-T Therapy, Primary Immunodeficiency
- Trial name
- NCT04724642
- Where
- Israel
- Volunteers
- 110 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
COVID-19, SARS-CoV-2
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly…
- Trial name
- NCT04847102
- Testing
- SARS-CoV-2 mRNA Vaccine
- Where
- 12 sites in Indonesia, Mexico
- Volunteers
- 28,000 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Covid19
COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19.
- Trial name
- NCT04843722
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
COVID-19
Puerto Rico COVID-19 Vaccine Uptake Study
The purpose of this study is to recruit a total of 386 participants to evaluate the effectiveness of an educational program to increase the proportion of men and women aged 21 years and older who have received the COVID-19…
- Trial name
- PR-COVACUPS (NCT05468021)
- Testing
- Educational intervention
- Where
- 2 sites in Puerto Rico
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- University of Puerto Rico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.